Ropes & Gray Advised Genesis in Collaboration with Incyte to Accelerate AI-Enabled Drug Discovery

Ropes & Gray advised Genesis Molecular AI in the significant expansion of its strategic collaboration with Incyte to build and deploy state-of-the-art AI to accelerate discovery of novel molecules for collaboration targets selected by Incyte. The expanded agreement was announced on May 20, 2026.

Incyte experimental data will be securely used to train Genesis’ next-generation GEMS AI platform as part of Incyte’s efforts to speed up drug development across multiple programs. Genesis will receive total upfront consideration of $120 million, which includes an $80 million upfront cash payment and a $40 million purchase of equity in Genesis. In addition, Incyte will also provide recurring research funding to Genesis to support AI model training and inference compute workloads.

Genesis Molecular AI is pioneering foundation models for molecular AI to unlock a new era of agentic drug design and development. The company’s generative and predictive AI platform, GEMS (Genesis Exploration of Molecular Space), integrates AI and physics into industry-leading models to generate and optimize drug molecules

The Ropes & Gray team included emerging companies & venture capital partner Brad Flint, IP transactions partner Megan Baca and counsel Joshua Jackson, life sciences licensing associate Amanda White, and emerging companies & venture capital associate Jordan Kiellach.